Anne Walter
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Anne Walter has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
Alexander Knuth
Authors' Affiliations: 1Laboratory of Tumor Immunology, Department of Oncology, 2Department of Dermatology, and 3Department of Pathology, University Hospital Zurich, Zurich, Switzerland; and 4Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan-Kettering Cancer Center, New York, New York
1 shared publicationBruno Schmid
Authors' Affiliations: 1Laboratory of Tumor Immunology, Department of Oncology, 2Department of Dermatology, and 3Department of Pathology, University Hospital Zurich, Zurich, Switzerland; and 4Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan-Kettering Cancer Center, New York, New York
1 shared publication- Erika Ritter
Department of Immunology, Sloan-Kettering Institute, Memorial Sloan-Kettering Cancer Center, New York, NY
1 shared publication Glen Kristiansen
Authors' Affiliations: 1Laboratory of Tumor Immunology, Department of Oncology, 2Department of Dermatology, and 3Department of Pathology, University Hospital Zurich, Zurich, Switzerland; and 4Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan-Kettering Cancer Center, New York, New York
1 shared publicationHolger Moch
Authors' Affiliations: 1Laboratory of Tumor Immunology, Department of Oncology, 2Department of Dermatology, and 3Department of Pathology, University Hospital Zurich, Zurich, Switzerland; and 4Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan-Kettering Cancer Center, New York, New York
1 shared publication- Maries van Den Broek
Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland
1 shared publication
Latest Publications
- Open Access
- 14 July 2010
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 16 (14) , 3562-3570
Cancer-Testis Antigens and Immunosurveillance in Human Cutaneous Squamous Cell and Basal Cell Carcinomas
Purpose: Nonmelanoma skin cancer is the most common cancer and comprises basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). The incidence of SCC increases drastically in immunosuppressed individuals, suggesting a critical role of the immune system in controlling SCC. To find an explanation for the selective immunosurveillance of SCC, we investigated the expression of cancer-testis (CT) antigens and MHC class I (MHC-I) and the infiltration by immune cells in BCC and SCC. Experimental Design: We determined the expression of 23 different CT-antigens in 63 BCC and 40 SCC biopsies of immunocompetent and in 20 biopsies of immunosuppressed SCC patients by reverse transcription-PCR and immunohistochemistry. IgG responses to 36 tumor antigens were measured by Western blotting and ELISA. MHC-I expression and CD8+ T-cell infiltration were analyzed by immunohistochemistry in BCC and SCC of immunocompetent and immunosuppressed patients and in imiquimod-treated BCC patients. Results: We found expression of at least one CT-antigen in 81% of BCC and in 40% of SCC. We did not detect CT-antigen–specific serum IgG. Most SCC, but not BCC, expressed MHC-I and were infiltrated with CD8+ cells. Imiquimod-treated BCC expressed MHC-I and were infiltrated by CD8+ T cells. Conclusions: We propose that immunosurveillance controls SCC, but not BCC, because the latter lacks MHC-I. This fits with the increased incidence of SCC in immunosuppressed individuals and may explain the relatively low prevalence of CT-antigen expression in SCC as a result of CD8+ T-cell–driven immunoediting. Clin Cancer Res; 16(14); 3562–70. ©2010 AACR.
- 14 July 2010
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 16 (14) , 3562-3570
Open AccessCancer-Testis Antigens and Immunosurveillance in Human Cutaneous Squamous Cell and Basal Cell Carcinomas
Purpose: Nonmelanoma skin cancer is the most common cancer and comprises basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). The incidence of SCC increases drastically in immunosuppressed individuals, suggesting a critical role of the immune system in controlling SCC. To find an explanation for the selective immunosurveillance of SCC, we investigated the expression of cancer-testis (CT) antigens and MHC class I (MHC-I) and the infiltration by immune cells in BCC and SCC. Experimental Design: We determined the expression of 23 different CT-antigens in 63 BCC and 40 SCC biopsies of immunocompetent and in 20 biopsies of immunosuppressed SCC patients by reverse transcription-PCR and immunohistochemistry. IgG responses to 36 tumor antigens were measured by Western blotting and ELISA. MHC-I expression and CD8+ T-cell infiltration were analyzed by immunohistochemistry in BCC and SCC of immunocompetent and immunosuppressed patients and in imiquimod-treated BCC patients. Results: We found expression of at least one CT-antigen in 81% of BCC and in 40% of SCC. We did not detect CT-antigen–specific serum IgG. Most SCC, but not BCC, expressed MHC-I and were infiltrated with CD8+ cells. Imiquimod-treated BCC expressed MHC-I and were infiltrated by CD8+ T cells. Conclusions: We propose that immunosurveillance controls SCC, but not BCC, because the latter lacks MHC-I. This fits with the increased incidence of SCC in immunosuppressed individuals and may explain the relatively low prevalence of CT-antigen expression in SCC as a result of CD8+ T-cell–driven immunoediting. Clin Cancer Res; 16(14); 3562–70. ©2010 AACR.